Merck and Moderna report Phase 3 topline gains for INTerpath-001 in resected stage IIB-IV melanoma

Merck and Moderna said they have generated positive topline results from their Phase 3 INTerpath-001 trial testing a combination therapy in patients with completely resected stage IIB-IV melanoma. The treatment pairs Moderna’s intismeran autogene with Merck’s KEYTRUDA, an immunotherapy designed to help the immune system recognize and attack cancer cells.

In a joint announcement dated August 19, 2026, the companies said the study met two key efficacy endpoints: recurrence-free survival (RFS) and distant metastasis-free survival (DMFS). RFS measures the length of time patients live without the melanoma returning, while DMFS tracks time until cancer spreads to distant sites.

The trial population includes people with stage IIB-IV melanoma whose tumors were completely removed, placing the study in the adjuvant setting. In adjuvant trials, sponsors generally focus on whether a therapy can reduce the risk of recurrence after surgery, particularly in higher-risk stages where microscopic disease may remain.

Merck noted in the release that it is known as MSD outside the United States and Canada, reflecting how the companies brand the same corporate entity across markets. Moderna trades on the Nasdaq under the ticker MRNA, while Merck trades as MRK on the NYSE.

KEYTRUDA is a well-established anti-PD-1 therapy. In combination with a next-generation messenger RNA (mRNA)-based approach, INTerpath-001 reflects a broader industry strategy of pairing immunotherapies with individualized or immune-modulating components to improve outcomes for patients at high risk of recurrence.

For Moderna, the readout is another attempt to translate mRNA biology into oncology endpoints that matter clinically, beyond early-stage safety indicates. For Merck, the results provide data supporting the expansion of KEYTRUDA-based regimens into earlier and higher-risk disease settings, where preventing relapse is often a primary goal.

The companies’ announcement, as presented in the post, does not include additional details such as hazard ratios, p-values, median follow-up duration, or whether any specific subgroup results were emphasized. It also does not lay out safety findings, including the incidence of immune-related adverse events, which would typically be critical for interpreting a Phase 3 topline release.

Going forward, investors and clinicians will likely look for the full Phase 3 data set, including safety, the magnitude of benefit for RFS and DMFS, and any descriptive details about dosing and patient characteristics. A subsequent presentation or regulatory filing could further clarify how the combination compares with standard adjuvant options and whether the results persist across longer follow-up.